Forecast
There is no analyst data available for this company.
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
Photocure increases currency-adjusted product revenue by 18% in Q1 2026
Photocure reports currency-adjusted product revenue growth of 18% for Q1 2026 and total revenue of NOK 264.6 million, significantly beating analyst estimates. Drivers were accelerated adoption of blue-light cystoscopy (BLC) in North America (26%) and Europe (11%) as well as milestone payments from partner Asieris. Adjusted EBITDA improved to NOK 15.3 million (Marche 11%), but reported EPS was -0.01 and missed expectations. Photocure confirms its 2026 guidance with expected currency-adjusted product revenue growth of 7–11% and further expansion of its market position for BLC. » More on de.investing.com
Photocure exceeds sales expectations in Q2 2025 and shares rise sharply
Photocure surpassed forecasts in the second quarter of 2025 with revenue of NOK 135.6 million, achieving 11% growth. The company reported positive EBITDA and a 12.01% increase in its share price, driven by strong results in North America and Europe as well as innovative product developments. Management confirmed its growth outlook and emphasized a strategic focus on expansion and partnerships. » More on de.investing.com
Photocure achieves record revenue in the second quarter of 2025 and focuses on strategic expansion
Photocure reported record revenue of NOK 135.6 million in the second quarter of 2025, representing 11% growth year-on-year. The company benefited from strong performance in North America and Europe, improved operational efficiency, and strategic partnerships and expansions, particularly in the US, Europe, and China. Photocure confirmed its 2025 outlook and believes it is well positioned for further growth through investments and innovation. » More on de.investing.com
Historical dividends Dividends
All dividend metrics All metricsIn 2013, PhotoCure has already paid €0.26 in dividends. The last payout was in June 2013.
Financials
In the last quarter, PhotoCure had revenue of €12.93M and net profit of -€2.4M
| (EUR) | September 2026 | YoY |
|---|---|---|
| Revenue | 12.93M | 12.30% |
| Gross profit | 11.34M | 14.89% |
| Net profit | -2.4M | 807.67% |
| EBITDA | 3.95M | 220.87% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €102.85M |
Number of shares | 26.97M |
52-week high/low | €7.43 - €3.81 |
| Dividends | No |
Beta | 0.35 |
P/E ratio | 22.37 |
PEG ratio | 0.00 |
P/B ratio | 1.91 |
P/S ratio | 1.62 |
Company profile
Photocure ASA, a specialty pharmaceutical company, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries, Germany, France, Austria, the United Kingdom, the Netherlands, Italy, other European Countries, and the United States. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus infection and precancerous lesions of the cervix. The company sells its products to pharmaceutical wholesalers, pharmacies, and hospitals through license partners. Photocure ASA was founded in 1993 and is headquartered in Oslo, Norway.
| Name | PhotoCure |
| CEO | Daniel Schneider |
| Headquarters | Oslo,
ps Norway |
| Website | |
| IPO | 05/30/2000 |
| Employees | 101 |
Deep Dive
Ticker symbols
| Exchange | Symbol |
|---|---|
Osl | PHO.OL |
London Stock Exchange | 0IMT.L |
Pnk | PHCUF |
Frankfurt | PHS.F |
Düsseldorf | PHS.DU |
London | 0IMT.L |